David O’Malley, Professor and Division Director of Gynecologic Oncology, Co-Director, The Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute, shared a post by Brian Slomovitz, Director of Gynecologic Oncology at Mount Sinai Medical Center Miami Beach, on LinkedIn, adding:
“Amazing opportunity for our patients with low grade serous ovarian cancer – confirmed ORR was 30.6%. Part of an amazing team The GOG Foundation, Inc and The Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute leading the way to deliver tomorrows therapies today.”
Quoting Brian Slomovitz‘s post:
“Not everyday we are fortunate enough to report we have a positive trial that may be incorporated in the standard of care. In Journal of Clinical Oncology ASCO the The GOG Foundation, Inc report on the combination of ribociclib Novartis and letrozole for the treatment of patients with Low Grade Serous Ovarian Cancer. 31% response rate with duration of response almost 2 years. 85% of patients had benefit to treatment.
Hoping to get National Comprehensive Cancer Network (NCCN) listing so we can get this combination to our patients ASAP.
Congrats to my colleagues who co-led this effort. It takes a team.”
Title: Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)
Authors: Brian M. Slomovitz, S. John Weroha, Wei Deng, Hye Sook Chon, Vivek Podder, Mary Tilley Jenkins Vogel, Floor Backes, Eric D. Thomas, Lee-May Chen, Meaghan Elizabeth Tenney, Shannon N. Westin, Merry Jennifer Markham, David S. Miller, Mitchell I. Edelson, Carolyn Y. Muller, Michael J. Callahan, Laura L. Holman, J. Rebecca Liu, Eleonora Teplinsky, Aparna Kamat, Michael Guy, Jing-Yi Chern, Jayanthi Lea, Martina Murphy, Grace M. Choong, Elena D. Moore, Edwin A. Alvarez, William H. Rodgers, David M. O’Malley, Larry J. Copeland, Thomas J. Herzog, Robert L. Coleman, and David M. Gershenson
Read The Full Article on Journal of Clinical Oncology
More posts featuring Ovarian Cancer on OncoDaily.